The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Small molecule orphan drugs: Balancing financial incentives and complex challenges
Whitepaper
For companies pursuing an orphan drug, successfully traversing the path to regulatory submission requires striking the right balance of speed-to-clinic and cost. While there is no one-size-fits-all approach, shared characteristics of successful development projects include:
- Early and frequent engagement with regulatory authorities
- Alignment of CMC and clinical activities
- Transparent communication among internal and external stakeholders
- An integrated vendor strategy
In this whitepaper, our experts help guide you through the complex challenges of getting your small molecule orphan drug to market faster.